Sana Biotechnology
Snehal Patel is the Head of Technical Operations at Sana Biotechnology. Snehal has a breadth of knowledge and experience in leading roles in Technical Operations, Technology, and Quality Assurance in Biologics, Small Molecules, and most recently in Cell Therapy.
Prior to Sana, Snehal was the Global Head and Vice President for Cell Therapy Manufacturing at Bristol Myers Squibb (BMS). He led the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including two cell therapies recently commercially launched in 2021 by BMS. Prior to this role he served as Site Head for Cell Therapy Manufacturing in Bothell, Washington. Prior to BMS, Snehal worked at Genentech/Roche for 18 years, holding a variety of different roles with increasing responsibility, including Head of Global External Drug Product Manufacturing, Head of Drug Product Operations, and Head of Quality Operations.
Snehal obtained a B.S. in Biological Sciences from California State University, East Bay.
Sana Biotechnology
2 followers
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy.